Article
TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
Antimicrobial agents and chemotherapy - 1 Dec 2011
Dierynck Inge, Van Marck Herwig, Van Ginderen Marcia, Jonckers Tim H M, Nalam Madhavi N L, Schiffer Celia A, Raoof Araz, Kraus Guenter, Picchio Gaston
Abstract excerpt
TMC310911 is a novel human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) structurally closely related to darunavir (DRV) but with improved virological characteristics. TMC310911 has potent activity against wild-type (WT) HIV-1 (median 50% effective concentration [EC(50)], 14 nM) and a wide spectrum of recombinant HIV-1 clinical isolates, including multiple-PI-resistant strains with decreased...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.